Literature DB >> 27815256

Toll-like receptor 4 activation attenuates profibrotic response in control lung fibroblasts but not in fibroblasts from patients with IPF.

Simone Ebener1,2,3, Sandra Barnowski1,3, Carlos Wotzkow1, Thomas M Marti1,4, Elena Lopez-Rodriguez5, Bruno Crestani6, Fabian Blank1, Ralph A Schmid1,4, Thomas Geiser1,3, Manuela Funke7,3.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease with a median survival of 3 yr. IPF deteriorates upon viral or bacterial lung infection although pulmonary infection (pneumonia) in healthy lungs rarely induces fibrosis. Bacterial lipopolysaccharide (LPS) activates Toll-like receptor 4 (TLR4), initiating proinflammatory pathways. As TLR4 has already been linked to hepatic fibrosis and scleroderma, we now investigated the role of TLR4 in IPF fibroblasts. Lung tissue sections from patients with IPF were analyzed for TLR4 expression. Isolated normal human lung fibroblasts (NL-FB) and IPF fibroblasts (IPF-FB) were exposed to LPS and transforming growth factor-β (TGF-β) before expression analysis of receptors, profibrotic mediators, and cytokines. TLR4 is expressed in fibroblast foci of IPF lungs as well as in primary NL-FB and IPF-FB. As a model for a gram-negative pneumonia in the nonfibrotic lung, NL-FB and IPF-FB were coexposed to LPS and TGF-β. Whereas NL-FB produced significantly less connective tissue growth factor upon costimulation compared with TGF-β stimulation alone, IPF-FB showed significantly increased profibrotic markers compared with control fibroblasts after costimulation. Although levels of antifibrotic prostaglandin E2 were elevated after costimulation, they were not responsible for this effect. However, significant downregulation of TGF-β receptor type 1 in control fibroblasts seems to contribute to the reduced profibrotic response in our in vitro model. Normal and IPF fibroblasts thus differ in their profibrotic response upon LPS-induced TLR4 stimulation.
Copyright © 2017 the American Physiological Society.

Entities:  

Keywords:  Toll-like receptor 4; connective tissue growth factor; fibroblasts; idiopathic pulmonary fibrosis; lipopolysaccharide

Mesh:

Substances:

Year:  2016        PMID: 27815256     DOI: 10.1152/ajplung.00119.2016

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  9 in total

1.  Heterogeneity of Fibroblasts and Myofibroblasts in Pulmonary Fibrosis.

Authors:  David M Habiel; Cory M Hogaboam
Journal:  Curr Pathobiol Rep       Date:  2017-05-02

2.  Pathogenesis and treatment of idiopathic and rheumatoid arthritis-related interstitial pneumonia. The possible lesson from COVID-19 pneumonia.

Authors:  A Manfredi; F Luppi; G Cassone; C Vacchi; C Salvarani; M Sebastiani
Journal:  Expert Rev Clin Immunol       Date:  2020-10-03       Impact factor: 4.473

Review 3.  Molecular Biomarkers in Idiopathic Pulmonary Fibrosis: State of the Art and Future Directions.

Authors:  Anna Stainer; Paola Faverio; Sara Busnelli; Martina Catalano; Matteo Della Zoppa; Almerico Marruchella; Alberto Pesci; Fabrizio Luppi
Journal:  Int J Mol Sci       Date:  2021-06-10       Impact factor: 5.923

Review 4.  Macrophage-stroma interactions in fibrosis: biochemical, biophysical, and cellular perspectives.

Authors:  Gwenda F Vasse; Mehmet Nizamoglu; Irene H Heijink; Marco Schlepütz; Patrick van Rijn; Matthew J Thomas; Janette K Burgess; Barbro N Melgert
Journal:  J Pathol       Date:  2021-03-03       Impact factor: 7.996

5.  Sevoflurane inhibits cardiac function in pulmonary fibrosis mice through the TLR4 signaling pathway.

Authors:  Yanan Cao; Zhenghua He; Maoen Zhu; Xiaowei Gao; Yue Yang; Junjie Zhang; Yundan Pan; Qulian Guo; Yonggang Peng; E Wang
Journal:  Pulm Circ       Date:  2018-08-30       Impact factor: 3.017

6.  Human microvasculature-on-a chip: anti-neovasculogenic effect of nintedanib in vitro.

Authors:  Soheila Zeinali; Colette A Bichsel; Nina Hobi; Manuela Funke; Thomas M Marti; Ralph A Schmid; Olivier T Guenat; Thomas Geiser
Journal:  Angiogenesis       Date:  2018-07-02       Impact factor: 9.596

7.  Azithromycin has enhanced effects on lung fibroblasts from idiopathic pulmonary fibrosis (IPF) patients compared to controls [corrected].

Authors:  Kristina Krempaska; Sandra Barnowski; Jacopo Gavini; Nina Hobi; Simone Ebener; Cedric Simillion; Andrea Stokes; Ronja Schliep; Lars Knudsen; Thomas K Geiser; Manuela Funke-Chambour
Journal:  Respir Res       Date:  2020-01-15

Review 8.  Regulation of cellular senescence by extracellular matrix during chronic fibrotic diseases.

Authors:  Kaj E C Blokland; Simon D Pouwels; Michael Schuliga; Darryl A Knight; Janette K Burgess
Journal:  Clin Sci (Lond)       Date:  2020-10-30       Impact factor: 6.124

9.  Extracellular CIRP Induces an Inflammatory Phenotype in Pulmonary Fibroblasts via TLR4.

Authors:  Siavash Bolourani; Ezgi Sari; Max Brenner; Ping Wang
Journal:  Front Immunol       Date:  2021-07-23       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.